Accepted Manuscript

The 2017 Royal Society Of Medicine Cystic Fibrosis Symposium

Assessment of liver disease in cystic fibrosis

Suzanne Davison

PII: S1526-0542(18)30071-X

DOI: https://doi.org/10.1016/j.prrv.2018.05.010

Reference: YPRRV 1266

To appear in: Paediatric Respiratory Reviews



Please cite this article as: S. Davison, Assessment of liver disease in cystic fibrosis, *Paediatric Respiratory Reviews* (2018), doi: https://doi.org/10.1016/j.prrv.2018.05.010

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Assessment of liver disease in cystic fibrosis

Suzanne Davison, Consultant Paediatric Hepatologist, Leeds Children's Hospital, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds LS1 3EX suzanne.davison@nhs.net

Disclosures

I have received consultancy fees and lecture fees from Gilead Science, Inc.

Key words

Cystic fibrosis liver disease Portal hypertension Oesophageal varices Liver transplantation

Abstract

Liver disease in cystic fibrosis has many causes, with biliary fibrosis due to abnormal CFTR protein predominating. Assessment requires aetiology to be defined. Biliary fibrosis may progress to cirrhosis and portal hypertension, which although initially asymptomatic, may cause varices and splenomegaly. Monitoring progression includes clinical and ultrasound assessment with endoscopic assessment of varices for those at risk. Extrapolated primarily from longitudinal assessment of viral hepatitis in adults, non-invasive elastography has a potential role. Evidence is lacking to support intervention strategies, but ursodeoxycholic acid and ligation of varices are widely applied. Indication and timing of liver transplantation are not clearly defined. Multidisciplinary approach is needed to tailor assessment and guide management.

Manuscript

Introduction

Liver disease may affect children and adults with cystic fibrosis (CF), although its significance, progression and impact on health may vary. Prevalence is reported to be between 10% and 30%, with onset of liver disease typically evident in the first decade, and prevalence of cirrhosis in children is suggested to be 5-10%. The Annual Report of UK Cystic Fibrosis Registry 2016 reports 1.3% prevalence of cirrhosis in those age < 16 and 3.7% age > 16. (1). However, epidemiological data are impacted on by the lack of consensus definition of liver disease, both relating to diagnostic criteria and also aetiology.

Aetiology

Download English Version:

https://daneshyari.com/en/article/8952764

Download Persian Version:

https://daneshyari.com/article/8952764

<u>Daneshyari.com</u>